2024-07 |
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study |
Clinical and Molecular Hepatology
|
2024-07 |
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma |
YONSEI MEDICAL JOURNAL
|
2024-07 |
Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007–2021: a nationwide, multicentre, retrospective cohort study |
EClinicalMedicine
|
2024-06 |
Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center |
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
|
2024-05 |
Appendicular Skeletal Muscle Mass to Visceral Fat Area Ratio Predicts Hepatic Morbidities |
GUT AND LIVER
|
2024-04 |
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease |
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
2024-04 |
High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study |
Alimentary Pharmacology and Therapeutics
|
2024-04 |
Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease |
European Journal of Gastroenterology and Hepatology
|
2024-03 |
A Liver Stiffness-Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma |
Clinical Gastroenterology and Hepatology
|
2024-03 |
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease |
Gut
|
2024-03 |
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study |
Metabolism: Clinical and Experimental
|
2024-01 |
Intact ketogenesis predicted reduced risk of moderate-severe metabolic-associated fatty liver disease assessed by liver transient elastography in newly diagnosed type 2 diabetes |
Frontiers in Endocrinology
|
2024-01 |
Fibrotic Burden in Patients With Hepatitis B Virus-Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes |
The Journal of Infectious Diseases
|
2024-01 |
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B |
Journal of Hepatology
|
2023-12 |
A multisociety Delphi consensus statement on new fatty liver disease nomenclature |
Journal of Hepatology
|
2023-11 |
Personalized Antiviral Drug Selection in Patients With Chronic Hepatitis B Using a Machine Learning Model: A Multinational Study |
AMERICAN JOURNAL OF GASTROENTEROLOGY
|
2023-11 |
Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma |
Cell Communication and Signaling
|
2023-11 |
Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: A competing risk analysis |
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
|
2023-10 |
Utility of fusion imaging for the evaluation of ultrasound quality in hepatocellular carcinoma surveillance |
ULTRASONOGRAPHY
|
2023-09 |
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study |
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
|
2023-08 |
Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus-related liver cirrhosis |
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
|
2023-08 |
An international multidisciplinary consensus statement on MAFLD and the risk of CVD |
HEPATOLOGY INTERNATIONAL
|
2023-08 |
Risk Stratification for Sarcopenic Obesity in Subjects With Nonalcoholic Fatty Liver Disease |
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
|
2023-08 |
Asia-Pacific association for study of liver guidelines on management of ascites in liver disease |
HEPATOLOGY INTERNATIONAL
|
2023-08 |
A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B |
Liver international : official journal of the International Association for the Study of the Liver
|
2023-08 |
ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis |
Clinical Gastroenterology and Hepatology
|
2023-07 |
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes |
Gut and Liver
|
2023-07 |
Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy |
Alimentary Pharmacology and Therapeutics
|
2023-05 |
The clinical effect of antiviral therapy in patients with hepatitis B virus-related decompensated cirrhosis and undetectable DNA |
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
|
2023-05 |
Inverse Propensity Score-Weighted Analysis of Entecavir and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B: A Large-Scale Multicenter Study |
Cancers
|
2023-04 |
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study |
Clinical and Molecular Hepatology
|
2023-03 |
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease |
Liver International
|
2023-03 |
Age, Sex, and Body Mass Index Should Be Considered When Assessing Spleen Length in Patients with Compensated Advanced Chronic Liver Disease |
Gut and Liver
|
2023-02 |
Hepatic Steatosis but not Fibrosis is independently associated with poor outcomes in patients with Inflammatory Bowel Disease |
JOURNAL OF CROHNS & COLITIS
|
2023-02 |
CAGE-B and SAGE-B models better predict the hepatitis B virus-related hepatocellular carcinoma after 5-year entecavir treatment than PAGE-B |
Journal of Digestive Diseases
|
2023-02 |
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future |
CLINICAL AND MOLECULAR HEPATOLOGY
|
2023-02 |
Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease |
Clinical Gastroenterology and Hepatology
|
2023-02 |
Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis |
Hepatology Communications
|
2023-02 |
Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma |
European Journal of Gastroenterology and Hepatology
|
2023-01 |
Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adults |
Clinical Hypertension
|
2023-01 |
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis |
DIAGNOSTICS
|
2023-01 |
Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma |
Frontiers in Endocrinology
|
2023-01 |
Self-Management and Associated Factors among Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study |
International Journal of Environmental Research and Public Health
|
2022-12 |
Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population |
Hepatology International
|
2022-11 |
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B |
Liver International
|
2022-10 |
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma |
Clinical and Molecular Hepatology
|
2022-10 |
Noninvasive surrogates are poor predictors of liver fibrosis in patients with Fontan circulation |
Journal of Thoracic and Cardiovascular Surgery
|
2022-10 |
MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups |
DIGESTIVE DISEASES AND SCIENCES
|
2022-09 |
Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study |
Diabetes and Metabolism
|
2022-09 |
The effect of pharmacological treatment and lifestyle modification in patients with nonalcoholic fatty liver disease: An umbrella review of meta-analyses of randomized controlled trials |
OBESITY REVIEWS
|
2022-08 |
Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease |
Abdominal Radiology
|
2022-08 |
Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model |
Gastroenterology Report
|
2022-08 |
Fibrotic burden during antiviral therapy for chronic hepatitis B, not ALT level, independently predicts liver cancer risk |
LIVER INTERNATIONAL
|
2022-08 |
Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma |
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
|
2022-07 |
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases |
Clinical and Molecular Hepatology
|
2022-07 |
Endoscopic variceal obturation and retrograde transvenous obliteration for acute gastric cardiofundal variceal bleeding in liver cirrhosis |
BMC GASTROENTEROLOGY
|
2022-07 |
Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study |
DIABETES & METABOLISM
|
2022-07 |
Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B |
Digestive Diseases and Sciences
|
2022-06 |
Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease |
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
|
2022-05 |
Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone |
Clinical Pharmacology in Drug Development
|
2022-05 |
Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B |
LIVER INTERNATIONAL
|
2022-05 |
Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis |
Cancers
|
2022-04 |
Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria |
Frontiers in Medicine
|
2022-04 |
Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B |
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
|
2022-04 |
Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B |
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
|
2022-04 |
Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study |
JOURNAL OF VIRAL HEPATITIS
|
2022-03 |
Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease |
Gut and Liver
|
2022-03 |
Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma |
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
|
2022-03 |
Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease |
GUT AND LIVER
|
2022-03 |
Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease |
DIABETOLOGIA
|
2022-03 |
Clinical significance of hepatosplenic thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination |
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
|
2022-02 |
Predictors of Sarcopenia in an Obese Asian Population |
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
|
2022-02 |
A micellized bone morphogenetic protein-7 prodrug ameliorates liver fibrosis by suppressing transforming growth factor- β signaling |
AMERICAN JOURNAL OF CANCER RESEARCH
|
2022-02 |
External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study |
Cancers
|
2022-02 |
Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis |
Diagnostics
|
2022-02 |
Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA ,2,000 IU/mL |
AMERICAN JOURNAL OF GASTROENTEROLOGY
|
2022-01 |
Metabolic Dysfunction–Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study |
Clinical and Translational Gastroenterology
|
2022-01 |
Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B |
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
|
2022-01 |
Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients |
Cancers
|
2022-01 |
Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization |
Cancers
|
2021-12 |
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients |
HEPATOLOGY INTERNATIONAL
|
2021-12 |
Novel liver stiffness-based nomogram for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection initiating antiviral therapy |
Cancers
|
2021-11 |
No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B |
JOURNAL OF VIRAL HEPATITIS
|
2021-11 |
A qualitative study of self-management experiences in people with non-alcoholic fatty liver disease |
Nursing Open
|
2021-10 |
Dickkopf-1 promotes angiogenesis by upregulating VEGF receptor 2-mediated mTOR/p70S6K signaling in hepatocellular carcinoma |
AMERICAN JOURNAL OF CANCER RESEARCH
|
2021-10 |
Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease |
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
|